Metabolic syndrome ‘better prognostic indicator’ for severe
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The odds for severe COVID-19 outcomes are increased for patients with metabolic syndrome, according to a study published in the Journal of Diabetes.

Metabolic syndrome (MetS) is highly prevalent worldwide, and its individual components obesity, diabetes, and hypertension have been identified as risk factors to develop severe COVID-19; however, data on MetS and clinical outcomes in COVID-19 are scarce. This study aims to determine association between MetS and severe disease outcomes, that is, mortality, need for mechanical ventilation, and intensive care unit (ICU) requirement among patients with COVID-19.

This is a retrospective multihospital cohort study on 1871 patients with confirmed COVID-19 diagnosis. Patient data including demographics, comorbidities, body mass index (BMI), smoking, laboratory data, and the clinical course of hospitalization were collected. Multivariable regression was performed adjusting for age, sex, race, insurance, smoking, and comorbidities.

-- A total of 1871 patients (median age 66; 965 (51.6%) males; 1494 (80%) African Americans; median BMI 29.4 kg/m2; 573 (30.6%) patients with MetS) were included.

-- Patients with MetS had increased mortality, higher ICU admission, and increased need for mechanical ventilation.

-- Among individual comorbidities, diabetes had significant association with mortality, ICU admission, and need for mechanical ventilation.

Conclusively, MetS is a better prognostic indicator for severe disease outcomes in patients with COVID-19 than its individual components. Patients with MetS had significantly higher mortality, increased ICU admissions, and need for mechanical ventilation.